

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of
STEPHEN DONOVAN

Serial No: 10/752,871

Date Filed: JANUARY 6, 2004

For: INTRAVITREAL BOTULINUM TOXIN
IMPLANT

Examiner:

Group Art Unit: 1615

Confirmation No.: 4854

Irvine, California

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant's provide with regard to the patent application entitled INTRAVITREAL BOTULINUM TOXIN IMPLANT, filed herewith one copy of documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. These documents were disclosed in an International Search Report in the foreign counterpart of the above-identified application. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

/CLAUDE L. NASSIF/

Date: October 31, 2006

Claude L. Nassif, Ph.D., Reg. No. 52,061

Address all inquires and correspondence to:

Claude L. Nassif, Ph.D.
Allergan, Inc., Legal Department
2525 Dupont Drive
Irvine, CA 92612
Telephone: 714 246 6458
Fax: 714 246 4249

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17359-CON2-CIP1-CIP1 (BOT)	SERIAL NO.: 10/752,871
APPLICANT: STEPHEN DONOVAN	TITLE: INTRAVITREAL BOTULINUM TOXIN IMPLANT
FILING DATE: JANUARY 6, 2004	GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA						
	AB						
	AC						
	AD						
	AE						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA	WO99/37326	29JUL1999	PCT	A61K	9/16	Y
	BB						
	BC						
	BD						
	BE						
	BF						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	JANKOVIC J et al., " <i>Botulinum toxin treatment of tremors</i> ", <u>Neurology</u> , vol. 41, no. 8, August 1991, pp. 1185-1188
	CB	MAYSINGER D et al., " <i>Preparation and in vivo effect of microencapsulated cholinotoxin</i> ", <u>International Journal of Pharmaceutics</u> , vol. 63, no. 2, 15 September 1990, pp. 149-154
	CC	MEN Y et al., " <i>A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide</i> ", <u>Vaccine</u> , vol. 13, no. 7, 1995, pp. 683-689
	CD	
	CE	
	CF	

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.